{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:07:29Z","timestamp":1787771249063,"version":"build-2784847793"},"reference-count":46,"publisher":"American Society of Hematology","issue":"26","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,26]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Venetoclax, a first-in-class BH3 mimetic drug that targets B-cell lymphoma-2 (BCL-2), has improved the outcomes of patients with chronic lymphocytic leukemia (CLL). Early measurements of the depth of the venetoclax treatment response, assessed by minimal residual disease, are strong predictors of long-term clinical outcomes. However, there are limited data on the early changes induced by venetoclax treatment that might inform strategies to improve responses. To address this gap, we conducted longitudinal mass cytometric profiling of blood cells from patients with CLL during the first 5 weeks of venetoclax monotherapy. At baseline, we resolved CLL heterogeneity at the single-cell level to define multiple subpopulations in all patients based on proliferative, metabolic, and cell survival proteins. Venetoclax induced a significant reduction in all CLL subpopulations and caused rapid upregulation of the prosurvival BCL-2, BCL-extra large, and mantle cell lymphoma-1 proteins in surviving cells, which had reduced sensitivity to the drug. In mouse models, the venetoclax-induced elevation of survival proteins in B cells and CLL-like cells that persisted was recapitulated, and genetic models demonstrated that extensive apoptosis and access to the B-cell cytokine, B-cell activating factor (BAFF), were essential. Accordingly, in patients with CLL who were treated with venetoclax or the anti-CD20 antibody obinutuzumab there was marked elevation in BAFF and an increase in prosurvival proteins in leukemic cells that persisted. Overall, these data highlight the rapid adaptation of CLL cells to targeted therapies through homeostatic factors and support cotargeting of cytokine signals to achieve deeper and more durable long-term responses.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024024341","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T20:03:59Z","timestamp":1730232239000},"page":"2748-2761","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Venetoclax dose escalation rapidly activates a BAFF\/BCL-2 survival axis in chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7745-9755","authenticated-orcid":false,"given":"Meng-Xiao","family":"Luo","sequence":"first","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3963-0360","authenticated-orcid":false,"given":"Tania","family":"Tan","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7258-7272","authenticated-orcid":false,"given":"Marie","family":"Trussart","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1135-7879","authenticated-orcid":false,"given":"Annika","family":"Poch","sequence":"additional","affiliation":[{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"},{"name":"3The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Minh Hanh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"},{"name":"3The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5403-7998","authenticated-orcid":false,"given":"Terence P.","family":"Speed","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8322-9983","authenticated-orcid":false,"given":"Damien G.","family":"Hicks","sequence":"additional","affiliation":[{"name":"4School of Science, Computing and Engineering Technologies, Swinburne University of Technology, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3875-8872","authenticated-orcid":false,"given":"Esther","family":"Bandala-Sanchez","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4813-0827","authenticated-orcid":false,"given":"Hongke","family":"Peng","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0574-7544","authenticated-orcid":false,"given":"St\u00e9phane","family":"Chappaz","sequence":"additional","affiliation":[{"name":"5Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9020-1487","authenticated-orcid":false,"given":"Charlotte","family":"Slade","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2205-9057","authenticated-orcid":false,"given":"Daniel T.","family":"Utzschneider","sequence":"additional","affiliation":[{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"},{"name":"3The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1627-8934","authenticated-orcid":false,"given":"Rachel M.","family":"Koldej","sequence":"additional","affiliation":[{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"},{"name":"6Australian Cancer Research Foundation Translational Research Laboratory, The Royal Melbourne Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7329-6605","authenticated-orcid":false,"given":"David","family":"Ritchie","sequence":"additional","affiliation":[{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"},{"name":"6Australian Cancer Research Foundation Translational Research Laboratory, The Royal Melbourne Hospital, Melbourne, VIC, Australia"},{"name":"7Department of Haematology, The Royal Melbourne Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Strasser","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4493-306X","authenticated-orcid":false,"given":"Rachel","family":"Thijssen","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7383-0609","authenticated-orcid":false,"given":"Matthew E.","family":"Ritchie","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-5017","authenticated-orcid":false,"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[{"name":"5Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia"},{"name":"8Alfred Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9386-2416","authenticated-orcid":false,"given":"Geoffrey J.","family":"Lindeman","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"},{"name":"9Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3101-4873","authenticated-orcid":false,"given":"David C. S.","family":"Huang","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-2432","authenticated-orcid":false,"given":"Thomas E.","family":"Lew","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"},{"name":"7Department of Haematology, The Royal Melbourne Hospital, Melbourne, VIC, Australia"},{"name":"9Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3515-0215","authenticated-orcid":false,"given":"Mary Ann","family":"Anderson","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"},{"name":"7Department of Haematology, The Royal Melbourne Hospital, Melbourne, VIC, Australia"},{"name":"9Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-5720","authenticated-orcid":false,"given":"Andrew W.","family":"Roberts","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"},{"name":"7Department of Haematology, The Royal Melbourne Hospital, Melbourne, VIC, Australia"},{"name":"9Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9745-2876","authenticated-orcid":false,"given":"Charis E.","family":"Teh","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8457-8242","authenticated-orcid":false,"given":"Daniel H. D.","family":"Gray","sequence":"additional","affiliation":[{"name":"1The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2024122616205730700_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.beha.2010.02.001","article-title":"Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells","volume":"23","author":"Damle","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"issue":"9","key":"2024122616205730700_bib2","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.3324\/haematol.2020.268037","article-title":"Targeting the tumor microenvironment in chronic lymphocytic leukemia","volume":"106","author":"Svanberg","year":"2021","journal-title":"Haematologica"},{"issue":"9","key":"2024122616205730700_bib3","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/blood.V91.9.3379","article-title":"Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in\u00a0vitro and in\u00a0vivo chemoresponses","volume":"91","author":"Kitada","year":"1998","journal-title":"Blood"},{"issue":"4","key":"2024122616205730700_bib4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024122616205730700_bib5","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"2024122616205730700_bib6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"23","key":"2024122616205730700_bib7","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2024122616205730700_bib8","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2024122616205730700_bib9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"25","key":"2024122616205730700_bib10","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","article-title":"The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism","volume":"127","author":"Anderson","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2024122616205730700_bib11","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"issue":"10","key":"2024122616205730700_bib12","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1182\/blood.2019004205","article-title":"Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax","volume":"135","author":"Blombery","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2024122616205730700_bib13","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"issue":"4","key":"2024122616205730700_bib14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies","volume":"36","author":"Guieze","year":"2019","journal-title":"Cancer Cell"},{"issue":"8","key":"2024122616205730700_bib15","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/blood.2021012775","article-title":"Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL","volume":"139","author":"Blombery","year":"2022","journal-title":"Blood"},{"issue":"25","key":"2024122616205730700_bib16","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","article-title":"Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax","volume":"129","author":"Anderson","year":"2017","journal-title":"Blood"},{"issue":"20","key":"2024122616205730700_bib17","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2022016040","article-title":"Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy","volume":"140","author":"Thijssen","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2024122616205730700_bib18","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/10428194.2021.1986217","article-title":"Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial","volume":"63","author":"Cochrane","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"2024122616205730700_bib19","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2024122616205730700_bib20","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2159-8290.CD-18-1151","article-title":"A\u00a0Phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2-positive metastatic breast cancer","volume":"9","author":"Lok","year":"2019","journal-title":"Cancer Discov"},{"issue":"12","key":"2024122616205730700_bib21","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/bloodadvances.2022008221","article-title":"Venetoclax treatment in cancer patients has limited impact on circulating T and NK cells","volume":"7","author":"Teh","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"2024122616205730700_bib22","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1038\/s41418-020-0498-z","article-title":"Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells","volume":"27","author":"Teh","year":"2020","journal-title":"Cell Death Differ"},{"key":"2024122616205730700_bib23","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.12688\/f1000research.26073.1","article-title":"An R-based reproducible and user-friendly preprocessing pipeline for CyTOF data","volume":"9","author":"Crowell","year":"2020","journal-title":"F1000Res"},{"key":"2024122616205730700_bib24","doi-asserted-by":"crossref","first-page":"e59630","DOI":"10.7554\/eLife.59630","article-title":"Removing unwanted variation with CytofRUV to integrate multiple CyTOF datasets","volume":"9","author":"Trussart","year":"2020","journal-title":"Elife"},{"key":"2024122616205730700_bib25","doi-asserted-by":"crossref","first-page":"748","DOI":"10.12688\/f1000research.11622.1","article-title":"CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets","volume":"6","author":"Nowicka","year":"2017","journal-title":"F1000Res"},{"issue":"6","key":"2024122616205730700_bib26","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/cyto.b.20613","article-title":"Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up--a GEIL-GOELAMS study","volume":"80","author":"Durrieu","year":"2011","journal-title":"Cytometry B Clin Cytom"},{"issue":"2","key":"2024122616205730700_bib27","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1084\/jem.155.2.623","article-title":"Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia","volume":"155","author":"Caligaris-Cappio","year":"1982","journal-title":"J\u00a0Exp Med"},{"issue":"11-12","key":"2024122616205730700_bib28","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.2119\/molmed.2011.00360","article-title":"Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born\/divided and older\/quiescent cells","volume":"17","author":"Calissano","year":"2011","journal-title":"Mol Med"},{"issue":"17","key":"2024122616205730700_bib29","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1182\/bloodadvances.2020003944","article-title":"Extrinsic interactions in the microenvironment in\u00a0vivo activate an antiapoptotic multidrug-resistant phenotype in CLL","volume":"5","author":"Jayappa","year":"2021","journal-title":"Blood Adv"},{"issue":"25","key":"2024122616205730700_bib30","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2019004326","article-title":"Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL","volume":"136","author":"Haselager","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2024122616205730700_bib31","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/leu.2014.1","article-title":"Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199","volume":"28","author":"Khaw","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2024122616205730700_bib32","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","article-title":"Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members","volume":"9","author":"Certo","year":"2006","journal-title":"Cancer Cell"},{"issue":"19","key":"2024122616205730700_bib33","doi-asserted-by":"crossref","first-page":"e121438","DOI":"10.1172\/jci.insight.121438","article-title":"Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies","volume":"3","author":"ten Hacken","year":"2018","journal-title":"JCI Insight"},{"issue":"4","key":"2024122616205730700_bib34","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/leu.2017.321","article-title":"Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy","volume":"32","author":"Patel","year":"2018","journal-title":"Leukemia"},{"issue":"7","key":"2024122616205730700_bib35","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nri844","article-title":"BAFF: a fundamental survival factor for B cells","volume":"2","author":"Mackay","year":"2002","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2024122616205730700_bib36","doi-asserted-by":"crossref","first-page":"109430","DOI":"10.1016\/j.celrep.2021.109430","article-title":"Homeostatic apoptosis prevents competition-induced atrophy in follicular B cells","volume":"36","author":"Chappaz","year":"2021","journal-title":"Cell Rep"},{"issue":"4","key":"2024122616205730700_bib37","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1182\/blood-2006-05-021683","article-title":"Differential Noxa\/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity","volume":"109","author":"Smit","year":"2007","journal-title":"Blood"},{"issue":"18","key":"2024122616205730700_bib38","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1182\/blood-2008-08-173310","article-title":"Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia","volume":"113","author":"Vogler","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2024122616205730700_bib39","doi-asserted-by":"crossref","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid"},{"issue":"4","key":"2024122616205730700_bib40","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"2024122616205730700_bib41","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1111\/febs.14505","article-title":"Phosphorylation alters Bim-mediated Mcl-1 stabilization and priming","volume":"285","author":"Conage-Pough","year":"2018","journal-title":"FEBS J"},{"issue":"2","key":"2024122616205730700_bib42","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1083\/jcb.200708096","article-title":"A\u00a0novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation","volume":"180","author":"Lee","year":"2008","journal-title":"JCB (J Cell Biol)"},{"issue":"12","key":"2024122616205730700_bib43","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.neo.2014.10.002","article-title":"Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia","volume":"16","author":"Balakrishnan","year":"2014","journal-title":"Neoplasia"},{"issue":"3","key":"2024122616205730700_bib44","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1182\/bloodadvances.2018025684","article-title":"Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib","volume":"3","author":"McWilliams","year":"2019","journal-title":"Blood Adv"},{"issue":"7","key":"2024122616205730700_bib45","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/s41418-020-0496-1","article-title":"NF-\u03baB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia","volume":"27","author":"Sanchez-Lopez","year":"2020","journal-title":"Cell Death Differ"},{"issue":"10","key":"2024122616205730700_bib46","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.3390\/cancers12102725","article-title":"Neutralization of B-cell activating factor (BAFF) by belimumab reinforces small molecule inhibitor treatment in chronic lymphocytic leukemia","volume":"12","author":"Tandler","year":"2020","journal-title":"Cancers (Basel)"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/26\/2748\/2349229\/blood_bld-2024-024341-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/26\/2748\/2349229\/blood_bld-2024-024341-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T16:21:16Z","timestamp":1735230076000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/26\/2748\/525813\/Venetoclax-dose-escalation-rapidly-activates-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,26]]},"references-count":46,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2024,12,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024341","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,26]]}}}